Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
A complete regimen offering convenient dosing for your patients¹
One pill once a day
No time-of-day restrictions
Can be taken with or without food
Few significant drug-drug interactions
A separate preparation of dolutegravir is available where a dose adjustment is indicated due to drug-drug interactions (e.g. rifampicin, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St. John’s wort, etravirine (without boosted protease inhibitors), efavirenz, nevirapine, or tipranavir/ritonavir. In these cases the physician should refer to the individual product information for dolutegravir.
Co-administration with medicinal products with narrow therapeutic windows, that are substrates of organic cation transporter (OCT) 2, including but not limited to fampridine (also known as dalfampridine) is contraindicated.
For further information on the DDI profile of Dovato please refer to the Summary of Product Characteristics.
DDIs Between EACS-Recommended Initial Regimens Available as a Single Pill and 43 Commonly Prescribed Non-ARVs as Defined by EACS*
DDIs Between Single-Pill Regimens and Commonly Prescribed Non-ARVs²*
* Includes 43 non-ARVs across cardiovascular drugs, CNS drugs, anti-infectives and miscellaneous (eg, antacids, PPIs, H2 blockers, methadone and St John’s wort) included in EACS Guidelines as commonly co-prescribed or of particular clinical relevance. Original data source: University of Liverpool drug interaction data.²
†Contraindicated with fampridine.
References:
- DOVATO Summary of Product Characteristics. Last Accessed: December 2020. Available at: https://www.medicines.ie/medicines/dovato-50-mg-300-mg-film-coated-tablets-34871/spc
- European AIDS Clinical Society Guidelines. Version 10.1. October 2020. Last Accessed: December 2020. Available at: https://www.eacsociety.org/files/guidelines10.1.finalsept2020.pdf
- TRIUMEQ Summary of Product Characteristic. Last Accessed December 2020. Available at: https://www.medicines.ie/medicines/triumeq-50-mg-600-mg-300-mg-film-coated-tablets-34057/spc
Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse reactions can also be reported to the HPRA by calling (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.
Date of preparation: December 2020 PM-IE-DLL-WCNT-200021
